Loading...

REPL REPLIMUNE GROUP INC Operational Disruptions 8-K Filing

RPLM

RPL

REPLIMUNE GROUP INC

(REPL)

2024 8-K

Show Summary

Summary

Pre-Market Approval

Investor Meetings

Financial Statements

Board Appointment

Financial Results

Warrant Adjustment

Stock Offering Update

Financial Results

Financial Results and Corpo...

Securities Purchase Agreement

Data Updates and Topline Re...

Data Updates Announcement

Financial Results Announcement

Executive Leadership Transi...

Results of Operations and F...

Clinical Data Presentation

Loan Agreement Amendment

Data Updates and Developmen...

Earnings Reports

Appointment of CFO

Annual Meeting of Stockholders

Sales Agreement with Leerin...

Financial Results and Colla...

Appointment of Director

Financial Results and CFO R...

Regulation FD Disclosure

Earnings Reports

Management Changes

External Links:

Replimune Group, Inc. announced data updates from its RP1 and RP2 programs, including topline results from its IGNYTE clinical trial of RP1 plus nivolumab in anti-PD1 failed melanoma, with a response rate of 33.6% and durable responses lasting more than 6 months.

AI Assistant

REPLIMUNE GROUP INC

2024

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.